AbbVie, Nimble
AbbVie Buying Nimble Therapeutics for $200M to Boost Immunology Pipeline
AbbVie has agreed to buy privately held biotechnology company Nimble Therapeutics for $200 million in cash in a deal that bolsters the biopharmaceutical company's expansive immunology portfolio. AbbVie on Friday said the deal adds Nimble's lead asset,
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...
Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to ...
Shares of AbbVie Inc. ABBV inched 0.10% higher to $173.37 Friday, on what proved to be an all-around mixed trading session ...
Pharmaceutical giant AbbVie Inc. has agreed to acquire Madison's Nimble Therapeutics Inc. for $200 million in cash.
Buying Nimble Therapeutics represents AbbVie's latest deal to build out a pipeline in the wake of fading sales of its once ...
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...
AbbVie (ABBV) and Nimble Therapeutics announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in ...
The North Chicago-based drugmaker said it's received positive topline results in a Phase 3 trial of its investigational ...
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...
AbbVie has announced that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback